Genovis AB (publ.) (STO:GENO)
Sweden · Delayed Price · Currency is SEK 20.25
+0.20 (1.00%)
Jul 28, 2026, 5:29 PM CET
Genovis AB (publ.) Market Cap
Genovis AB (publ.) has a market cap or net worth of 1.35 billion as of July 28, 2026. Its market cap has decreased by -29.16% in one year.
Market Cap
1.35B
Enterprise Value
1.27B
Revenue
136.99M
Ranking
n/a
PE Ratio
64.76
Stock Price
20.25
ChartMarket Cap Chart
Since April 18, 2008, Genovis AB (publ.)'s market cap has increased from 7.51M to 1.35B, an increase of 17,901.40%. That is a compound annual growth rate of 32.84%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 28, 2026 | 1.35B | -3.65% |
| Dec 30, 2025 | 1.40B | -13.18% |
| Dec 30, 2024 | 1.62B | -52.50% |
| Dec 29, 2023 | 3.40B | 13.17% |
| Dec 30, 2022 | 3.01B | -37.05% |
| Dec 30, 2021 | 4.78B | 131.75% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vicore Pharma Holding AB | 3.18B |
| Egetis Therapeutics AB | 3.12B |
| Saniona AB | 1.81B |
| Flerie AB | 1.77B |
| BioInvent International AB | 1.54B |
| Medivir AB | 1.11B |
| SynAct Pharma AB | 1.03B |
| Infant Bacterial Therapeutics AB | 899.89M |